Who is sponsoring NCT05908019?

NCT05908019 is sponsored by National Defense Medical Center, Taiwan.

What drugs are being tested in NCT05908019?

Interventions in NCT05908019: Web-based health care program.

What condition does NCT05908019 study?

NCT05908019 studies Web-based Health Care Program.

Is NCT05908019 still recruiting?

NCT05908019 is currently status unknown. Last updated 18 June 2023.

Last reviewed 2023-06-18 · How we verify

NCT05908019: PAH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Pulmonary Hypertension Web-Based Health Care Program on Symptom Management, Social Support, Activity Tolerance, and Quality of Life in Patients With Pulmonary Hypertension.

Status unknown NA Last updated 18 June 2023

What this trial tests

NA trial testing Web-based health care program in Web-based Health Care Program in 100 participants. Status unknown.

Timeline

5 May 2023

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	National Defense Medical Center, Taiwan
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	100
Start date	5 May 2023
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across Taiwan

Drugs / interventions tested

Web-based health care program

Conditions studied

Web-based Health Care Program — all drugs for Web-based Health Care Program →

Sponsor

National Defense Medical Center, Taiwan

Who can join

Adults 20 to 90, any sex, with Web-based Health Care Program. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pulmonary arterial hypertension (PAH) is a chronic disease characterized by an elevation in pulmonary artery pressures and pulmonary vascular resistance. The condition most often is rarely detected, and patients frequently suffer symptoms for several years before being appropriately diagnosed. Patients with PH suffer from several symptoms, such as exertional dyspnea, fatigue, weakness, chest pain, fainting…et al. Pulmonary hypertension is an incurable and progressive disease with complex symptoms and treatments. Patients must learn to deal with their unpredictable future and manage the complex treatments associated with severe adverse effects and need significant changes in lifestyle. Therefore, it is important to assist patients to develop the ability of symptom management.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of Web-Based Symptom Monitoring Program on Symptom Interference, Physical Activity, and Emergency Department Readmissions in Patients With Pre-Capillary Pulmonary Hypertension: Randomized Controlled Trial.
Chen MY, Wu CH, Cheng SM, Chen TY, et al · · 2025 · PMID 40958174 · DOI 10.2196/76883

Verify or expand the search:

Other National Defense Medical Center, Taiwan trials

Trials by the same sponsor.

NCT07373002 — Development and Evaluation of an Intelligent Parent-Infant Connection-Based Intervention to Strengthen Family Resilience · NA · not yet recruiting
NCT07488052 — Home-based Outpatient Multicenter Evaluation Using Electrocardiogram (HOME-ECG) · recruiting
NCT07307729 — AI-Enabled ECG Stratification and Timing of Potassium-Lowering Therapy in Patients With Hyperkalemia: A Target Trial Emu · NA · not yet recruiting
NCT07217236 — Proactive Risk Evaluation for Cardiac Implantable Electronic Device Strategy Using AI-ECG · NA · recruiting
NCT06887699 — The Impact of Artificial Intelligence Electrocardiography on Occlusion Myocardial Infarction Management Under the Value- · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05908019 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Defense Medical Center, Taiwan
Last refreshed: 18 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05908019.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing